Prev Chronic Dis by Redwood, Diana et al.
Volume 11 — April 10, 2014ORIGINAL RESEARCH
Comparison of Fecal Occult Blood Tests for Colorectal 
Cancer Screening in an Alaska Native Population With 
High Prevalence of Helicobacter pylori Infection, 2008
–2012
Diana Redwood, PhD, MPH; Ellen Provost, DO, MPH; Elvin Asay, MS; Diana Roberts, MS; 
Donald Haverkamp, MPH; David Perdue, MD, MSPH; Michael G. Bruce, MD, MPH; Frank Sacco, 
MD; David Espey, MD
Suggested citation for this article: Redwood D, Provost E, Asay E, Roberts D, Haverkamp D, Perdue D, et al. Comparison 
of Fecal Occult Blood Tests for Colorectal Cancer Screening in an Alaska Native Population With High Prevalence of 





Alaska Native colorectal cancer (CRC) incidence and mortality rates are the highest of any ethnic/racial group in the 
United States. CRC screening using guaiac-based fecal occult blood tests (gFOBT) are not recommended for Alaska 
Native people because of false-positive results associated with a high prevalence of Helicobacter pylori-associated 
hemorrhagic gastritis. This study evaluated whether the newer immunochemical FOBT (iFOBT) resulted in a lower 
false-positive rate and higher specificity for detecting advanced colorectal neoplasia than gFOBT in a population with 
elevated prevalence of H. pylori infection.
Methods
We used a population-based sample of 304 asymptomatic Alaska Native adults aged 40 years or older undergoing 
screening or surveillance colonoscopy (April 2008–January 2012).
Results
Specificity differed significantly (P < .001) between gFOBT (76%; 95% CI, 71%–81%) and iFOBT (92%; 95% CI, 89%–
96%). Among H. pylori-positive participants (54%), specificity of iFOBT was even higher (93% vs 69%). Overall, 
sensitivity did not differ significantly (P = .73) between gFOBT (29%) and iFOBT (36%). Positive predictive value was 
11% for gFOBT and 32% for iFOBT.
Conclusion
The iFOBT had a significantly higher specificity than gFOBT, especially in participants with current H. pylori infection. 
The iFOBT represents a potential strategy for expanding CRC screening among Alaska Native and other populations 
with elevated prevalence of H. pylori, especially where access to screening endoscopy is limited.
Introduction
The incidence and mortality of colorectal cancer (CRC) among Alaska Native people is the highest of any ethnic or 
racial group in the United States (1). CRC is the leading incident cancer in Alaska Native people, who have nearly twice 
the incidence and mortality attributable to CRC as the general US population (2,3).
CRC can be treated more effectively if detected early using screening tests or even prevented through removal of 
precancerous lesions (4). CRC screening options include using a fecal occult blood test (FOBT), which detects blood in 
the stool resulting from CRC. Guaiac-based FOBT (gFOBT) detects the heme portion of hemoglobin. However, 
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bleeding from upper intestinal tract lesions, including erosions, ulcers, and hemorrhagic gastritis from Helicobacter 
pylori infection (5) or nonsteroidal anti-inflammatory medications (6) may cause gFOBT false-positive results, as can 
nonhuman heme from ingesting red meat or ingesting foods with peroxidase activity (eg, spinach). Ingestion of 
vitamin C may cause false-negative tests. Dietary and medication restrictions are necessary for accurate gFOBTs. CRC 
screening using gFOBT has been discouraged among Alaska Native people as outlined in the CRC screening guidelines 
of the Alaska Area Native Health Service of June 2008. A high prevalence of H. pylori infection, which affects up to 
75% of rural Alaska Native people (7), and the Alaska Native diet, which tends to be high in red meat (8), might 
contribute to false-positive gFOBTs and cause concern as to the overall reliability of the gFOBT in the Alaska Native 
population.
The immunochemical FOBT (iFOBT) detects the globin portion of human hemoglobin. Because globin is degraded as it 
transits the upper intestinal tract, iFOBT is used to detect lower intestinal bleeding. Dietary and medication 
restrictions are not required for iFOBT. For these reasons iFOBT has better specificity and equal or better sensitivity 
than gFOBT for the detection of colorectal neoplasms (9,10).
The purpose of this study was to evaluate whether iFOBT resulted in a lower false-positive rate and higher specificity 
than gFOBT for CRC screening in an Alaska Native population with elevated prevalence of H. pylori infection. 
Findings from this study may provide new evidence for use of iFOBT as a suitable alternative method of CRC screening 




From April 2008 through January 2012 the study recruited from 2,340 patients scheduled for screening or 
surveillance colonscopy at the Alaska Native Medical Center in Anchorage, Alaska (Figure). Eligibility criteria included 
Alaska Native; 40 years old or older; no history of CRC or inflammatory bowel disease (eg, ulcerative colitis, Crohn’s 
disease); and no family history of familial adenomatous polyposis (FAP) or hereditary nonpolyposis colorectal cancer. 
Exclusion criteria included anticoagulant use that could not be discontinued during the study; frank blood in the stool 
in the previous 4 weeks; or residence in a home without a flush toilet (stool tests required toilet bowl water for sample 
collection). We excluded from the analysis participants who chose not to proceed with colonoscopic follow-up. Of the 
700 total eligible adults, 397 (57%) were enrolled in the study. Of those, 304 (77%) completed the study.
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Figure. Flow diagram for enrollment in a study of fecal occult blood tests among Alaska Natives, Anchorage, Alaska, 
2008–2012. Abbreviations: CRC, colorectal cancer; iFOBT, immunochemical fecal occult blood test; gFOBT, guaiac-
based fecal occult blood test; H. pylori, Helicobacter plyori. [A text description of this figure is also available.]
The Alaska Area Institutional Review Board (IRB), the Indian Health Service IRB, and relevant tribal review 
committees approved the study protocol. The Centers for Disease Control and Prevention (CDC) Human Research 
Protection Office granted a reliance on the Alaska Area IRB for approval and oversight. Participants signed an 
informed consent before study enrollment.
Study procedures
All participants completed an intake questionnaire for the collection of demographic, CRC risk factor, and medical and 
family history information. Participants were asked about living outside of the United States to assess potential 
international exposure to H. pylori. We gave each participant a noninvasive 13C-urea breath test (UBT; BreathTek 
Otsuka America Pharmaceutical, Inc, Lafayette, Colorado; www.breathtek.com) to determine current H. pylori
infection status. As per clinical practice standards at the Alaska Native Medical Center, we informed participants with 
positive UBT results that, unless they had symptoms, treatment for H. pylori infection was not recommended. We 
asked persons with a negative UBT who were taking proton-pump inhibitors (PPIs) or bismuth-containing medication 
at study enrollment to retest after discontinuing PPIs for a minimum of 7 days to rule out false-negative UBTs.
We asked each participant within 7 days preceding the colonoscopy, but before starting the bowel preparation for the 
colonoscopy procedure, to complete a 3-card gFOBT (Hemoccult, Beckman Coulter, Fullerton, California) as well as a 
2-card iFOBT (InSure FIT, Enterix, Edison, New Jersey) as per manufacturer directions. To maximize accuracy of 
gFOBT results, we instructed participants to avoid red meats and vitamin C in excess of 250 mg/d from supplements, 
citrus fruit, and juices for 3 days before and during stool collection. We also instructed participants to avoid 
nonsteroidal anti-inflammatory medicines such as ibuprofen, naproxen, or aspirin (more than 1 adult aspirin per day) 
for 7 days before and during stool collection. Patients gathered samples from 3 subsequent days of bowel movements 
(BMs). They took 2 samples from each of the 3 BMs for the gFOBT and 1 sample from 2 BMs for the iFOBT. 
Participants obtained stool samples for the gFOBT using a dry plastic container placed over the toilet bowl. 
Participants collected a sample of the stool using a specimen collection stick and spread the sample on the gFOBT card. 
They then transferred the stool to the toilet water where they collected the iFOBT samples by brushing the surface of 
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the stool in the toilet water and applying the sample to the test card. They returned FOBTs to the study coordinators 
within 10 days of collection. Participants then had a screening or surveillance colonoscopy performed under conscious 
sedation by an endoscopist at the Alaska Native Medical Center. At the conclusion of all tests, participants completed a 
questionnaire assessing test instruction compliance and received a $75 gift card for their participation.
Interpretation of study tests
Study research nurses analyzed the gFOBT cards according to manufacturer specifications. Quest Diagnostics, Inc, in 
Seattle, Washington, analyzed the iFOBT cards. As per standard practice, if any window on the 6-sample gFOBT or 2-
sample iFOBT was positive, we considered that test positive. The 3 endoscopists and all pathologists were blinded to 
the FOBT results. CDC’s Arctic Investigations Program in Anchorage analyzed the H. pylori UBTs. Following 
colonoscopy, we classified participants on the basis of the most advanced lesion identified. To ensure quality control of 
data input, we randomly selected 20% of study records for validation with the original data sources (pathology reports, 
chart review, CDC laboratory, Quest Diagnostics, Inc).
Outcome measures and statistical analysis
We determined a projected sample size of 300 using the McNemar test procedure for matched pairs with 80% power 
and an α of .05. The primary interest was the difference in specificity between gFOBT and iFOBT, which we estimated 
to be between 8% and 11%. We estimated the negativity rate for advanced colorectal neoplasia at 90%. Advanced 
colorectal neoplasia included invasive carcinoma, cancer in situ, adenomas with villous or tubulovillous histology, or 
tubular adenomas 1 cm or larger.
We performed the statistical analysis with SAS software (version 9.2, SAS Institute Inc, Cary, North Carolina). We 
calculated proportions and confidence intervals (CIs) for categorical data. We used binomial and Fisher exact test to 
calculate CIs for the specificity (and sensitivity) of the iFOBT and gFOBT using the results of the colonoscopy as the 
gold standard. We used Trajman’s method for McNemar test to compare specificity (and sensitivity) between the 
iFOBT and gFOBT (11). We created CIs for the difference in specificity (and sensitivity) of the 2 tests using the method 
described by Hawass (12).
Results
The mean participant age was 56 years (62% female) (Table 1). The study included 156 participants (51%) who received 
a screening colonoscopy and 148 participants (49%) who received a surveillance colonoscopy. Eighty-eight participants 
(29%) had a family history of colorectal neoplasia, and 102 (34%) had a personal history of colorectal neoplasia.
Self-reported medical history that could be associated with a false-positive gFOBT included stomach ulcers (11%), 
gastritis (14%), stomach bleeding (6%), heartburn or gastroesophageal reflux disease (43%), and previous H. pylori
infection (8%). Only 12% had ever lived outside of the United States for more than 6 months. Most participants were 
able to follow study restrictions to avoid aspirin and nonsteroidal anti-inflammatory medications (71%) and foods and 
juices containing vitamin C (91%). However, only 57% were able to follow the red meat restrictions. Of the 304 
participants, 28 (9%) had advanced neoplasia. Of those with advanced neoplasia, 12 (43%) had tubular adenomas 1 cm 
or larger, 12 (43%) had tubulovillous, villous, or serrated adenomas, and 4 (14%) had adenocarcinomas. A total of 164 
participants (54%) were positive for H. pylori by UBT.
There was a nonsignificant 7 percentage-point difference in overall sensitivity between gFOBT and iFOBT (P = .73, 
95% CI, −13 to 27). For participants who tested positive for H. pylori, the difference in sensitivity was also 
nonsignificant at 4 percentage points (P = >.99, 95% CI, −20 to 29). Overall specificity for advanced neoplasia was 76% 
(95% CI, 71%–81%) for gFOBT and 92% (95% CI, 89%−96%) for iFOBT, a significant difference of 16 percentage 
points (P < .001, 95% CI, 10–22) (Table 2). Specificity did not differ significantly by sex or age. For H. pylori-positive 
participants, the difference in specificity (24 percentage points) between the 2 tests was even greater (P < .001, 95% CI, 
17−31). Among participants who were able to adhere to dietary and medication restrictions, specificity of gFOBT 
increased but was still significantly lower than iFOBT. Of the 4 patients identified with adenocarcinoma, 2 were 
identified by gFOBT and 1 by iFOBT.
Among 276 participants without advanced neoplasia, 67 (24%) had a false-positive gFOBT; only 21 (8%) were false 
positives with iFOBT (Table 3). For H. pylori-positive participants without advanced neoplasia (n = 143), a total of 44 
(31%) were falsely identified as positive by the gFOBT compared with 10 (7%) false positive by the iFOBT. For H. 
pylori-negative participants without advanced neoplasia (n = 133), 23 (17%) had a false positive gFOBT compared with 
11 (8%) false positives by iFOBT. The PPV for gFOBT was 11% whereas the PPV for iFOBT was 32%. Likelihood ratios 
for gFOBT were close to 1 for the total population and for H. pylori-positive and H. pylori-negative populations. 
Likelihood ratios for the iFOBT were 4.6 for the total population, 4.8 for H. pylori-positive populations, and 4.6 for H. 
pylori-negative populations.
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Discussion
There is widespread reluctance to use gFOBT for CRC screening in Alaska Native people because of a concern that the 
high prevalence of H. pylori infection and other factors lead to excessive false-positive tests and poor specificity. 
Haverkamp et al found that Alaska had the lowest percentage (54%) of tribal providers nationally that reported using 
FOBT for CRC screening (13). This study corroborates these concerns and indicates a substantial gain in specificity 
when using iFOBT compared with gFOBT. The advantages of iFOBT compared with gFOBT were most evident in 
participants with H. pylori infection. Other studies have reported specificities of gFOBT for detecting advanced 
neoplasia from 63% to 97% and of iFOBT from 60% to 99% (10,14–19). Test specificity in this study population fell 
within the previously reported upper range for iFOBT. Sensitivity for both tests was consistent with previous reports. 
The false-positive rate for both iFOBT (8%) and gFOBT (24%) was lower than previously reported (48% to 87%) in 
other studies, including a study in a Taiwanese population with a high prevalence of H. pylori infection, which showed 
an iFOBT false-positive rate of 59% (20).
As Alaska Native people have the highest CRC incidence and mortality of any US population, accessible and reliable 
CRC screening is a critical public health objective. Yet the reluctance to use FOBTs has led to a reliance on endoscopy, 
particularly colonoscopy, as the preferred CRC screening method in this population (21). Compared with stool tests, 
endoscopy requires specially trained providers, is resource intensive, and requires patients to undergo invasive bowel 
preparation and screening procedures. Furthermore, as elsewhere in the United States (22), endoscopic capacity is 
limited in Alaska, particularly at the regional health facilities that serve the Alaska Native population. For many Alaska 
Native people living in remote communities, obtaining screening endoscopy requires costly and time-consuming air 
travel to 1 of the 7 regional health facilities with endoscopic capacity or to Anchorage. Because of a shortage of trained 
local personnel, only 4 of these regional facilities provide endoscopy on a continuous basis, while 3 hold intermittent 
screening clinics staffed by itinerant endoscopists. Because of these geographic and health system barriers, there is a 
need to expand CRC screening options such as FOBT for Alaska Native people, particularly for those living in rural 
regions of the state.
Human infection with H. pylori is common (23). Our study of mostly urban Alaska Native adults found that 54% of 
participants were H. pylori-positive by UBT, which is higher than the US average seropositivity rate (31%) (24). These 
data may have relevance for other settings because of the high prevalence of H. pylori infection worldwide, especially 
in low-resource countries with less access to screening endoscopy and greater need of low-cost screening methods like 
stool testing.
The dietary modification required for gFOBT is also a challenge in the Alaska Native population. Study participants 
showed a high level of nonadherence to the gFOBT dietary restrictions, especially to red meat avoidance. Other studies 
have examined FOBT completion rates and dietary restriction (25,26), but none have assessed adherence by Alaska 
Native people to FOBT dietary restriction. Alaska Native people have historically lived entirely on foods hunted and 
gathered from the land and sea (traditional foods). Most Alaska Native diets were heavily meat- and fat-based, with 
few carbohydrates (8). Although store-bought foods have increasingly supplemented or supplanted traditional foods, 
Alaska Native people still acquire a high percentage of their protein and associated micronutrients from wild foods 
(27). This is especially so among Alaska Native elders, who tend to have a higher intake of traditional foods than their 
younger counterparts, including more fish, moose, seal, and walrus consumption (28). These traditional diet patterns, 
along with the higher expense of store-bought foods, may help to explain the apparent reluctance of study participants 
to avoid red meat as required for the gFOBT.
These data suggest that iFOBT offers advantages over gFOBT. Screening rates across the Alaska Tribal Health System 
(ATHS) are lower than rates among US whites, with 58% of age-appropriate Alaska Native people being up to date with 
CRC screening in 2012 (ATHS data, 2000–2012) (29). The use of iFOBT in other populations to increase adherence to 
CRC screening recommendations (30,31) may help increase CRC screening rates in Alaska Native people while 
allowing for prioritization of colonoscopy for diagnostic and surveillance examinations. The iFOBT is simple, 
convenient, relatively inexpensive, and does not require dietary or drug restrictions. However, as shown in our results, 
6% of participants had a false-negative iFOBT, and the iFOBT only correctly identified 1 of the 4 adenocarcinomas, 
which emphasizes the need for patient education to ensure annual iFOBT adherence to detect cancers that might be 
missed in the previous screening test cycle. Additionally, expanding screening options to include iFOBT would require 
multiple changes within the ATHS. These include system-wide policy changes approved by multiple tribal health care 
providers and tribal leadership; development of new health education materials for both patients and providers; 
systems changes to enable local laboratory processing of the iFOBT kits; and coordination of appropriate follow-up for 
positive results with diagnostic colonoscopy. A pilot intervention in 2 Alaskan regions is being planned to evaluate the 
feasibility and acceptability of iFOBT in the Alaska Native population, especially among persons who have previously 
refused screening by endoscopy. This pilot project aims to lay the groundwork for broader implementation of the use 
of iFOBT throughout the ATHS.
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The comparison of iFOBT to gFOBT study findings reported here are subject to several limitations. The small sample 
size limited the ability to stratify analysis by age group, sex, or subgroups such as those with advanced CRC neoplasia. 
Although the prevalence of advanced neoplasia among participants was high (9%), the absolute number of cases 
widened confidence intervals around the estimated sensitivity of both tests. The gFOBT was a 6-sample test, compared 
with the 2-sample iFOBT, which might have increased the potential for false-positive gFOBT compared with the iFOBT 
results. In addition, gFOBT and iFOBT are designed to screen for cancer, not advanced adenomas, which often do not 
cause fecal blood loss. Nonetheless, the differences demonstrated between the 2 tests in this population, especially 
among those with H. pylori infection as measured by UBT, show a higher comparative effectiveness of iFOBT to 
gFOBT. Lastly, this study only included Alaska Native adults living in an urban area of Alaska and may not reflect 
results of a similar study in Alaska Native residents in communities where H. pylori prevalence may be higher.
This study found that iFOBT had a significantly higher specificity than gFOBT, especially in participants with H. pylori
infection. The data provide strong evidence that would support a decision to offer iFOBT as an alternative for CRC 
screening in rural and remote populations with a limited capacity for screening colonoscopy. Furthermore, these data 
have relevance to the worldwide CRC screening of populations with high prevalence of H. pylori infection, many of 
which are also low-resource and have a greater need of low-cost screening methods like stool testing. Increasing the 
availability and types of tests for CRC screening may increase uptake of screening and may ultimately decrease the 
excess illness and death associated with this disease among Alaska Native people.
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Tables
Table 1. Demographics and Clinical Characteristics of Alaska Native People 
in Fecal Occult Blood Test (FOBT) Study, 2008–2012











Past history of colorectal neoplasia 102 (34)
Family history of colorectal neoplasia 88 (29)
Medical history
Stomach ulcers 34 (11)
Gastritis 41 (14)
Stomach bleeding 19 (6)
Heartburn or gastroesophageal reflux disease 131 (43)
Previous Helicobactor pylori infection 25 (8)
Ever lived outside of the United States >6 months 35 (12)
Current medications
Antibiotics in last 14 days 20 (7)
Use of proton-pump inhibitors 44 (14)
Use of bismuth-containing medications 19 (6)
Use of vitamin C 123 (40)
Use of aspirin 117 (38)
Use of nonsteroidal anti-inflammatory medications 142 (47)
Personal habits
Currently drink alcohol (mean alcoholic drinks per week = 7) 113 (37)
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Characteristic No. (%) of Participants
Currently smokes cigarettes (mean cigarettes per day = 9) 104 (34)
Ever used home stool test before 44 (14)
Test instruction adherence
Avoided aspirin and nonsteroidal anti-inflammatory medications 217 (71)
Avoided red meat 172 (57)
Avoided vitamin C, fruit, and fruit juices 276 (91)
Colonoscopy histology
No pathology reported 130 (43)
Normal biopsy 24 (8)
Hyperplastic 51 (17)
Adenoma, tubular <1 cm 66 (22)
Adenoma, tubular ≥1 cm 12 (4)
Adenoma, tubulovillous 10 (3)
Adenoma, villous 1 (0)
Adenoma, serrated >5 mm 1 (0)




Helicobacter pylori positive 164 (54)
Results do not add to 100% as participants could have more than 1 reason for colonoscopy.
Includes cancer in a first-degree relative only.
Includes history of self-reported risk factors that could be associated with a guaiac-based FOBT that was false positive.
Considered to be advanced neoplasia, defined as any of the following: 1) adenomas ≥1 cm, 2) high-grade dysplasia, 3) 
villous histology, or 4) carcinoma.
Table 2. Sensitivity and Specificity of Guaiac-Based Fecal Occult Blood Test 
(gFOBT) and Immunochemical Fecal Occult Blood Test (iFOBT) for 
Detection of Advanced Neoplasia Among Alaska Native People by Helicobacter 
pylori Infection Status, 2008–2012
H. pylori status/Test Used Sensitivity, % (95% CI) Specificity, % (95% CI) PPV, % (95% CI)
Total study population (n = 304)
gFOBT 29 (12–45) 76 (71–81) 11 (4–17)
iFOBT 36 (18–53) 92 (89–96) 32 (16–49)
H. pylori-positive (n = 164)
gFOBT 29 (9–48) 69 (62–77) 12 (3–21)
iFOBT 33 (13–54) 93 (89–97) 41 (18–65)
H. pylori-negative (n = 140)
gFOBT 29 (4–71) 83 (76–89) 8 (1–26)
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Abbreviations: CI, confidence interval; PPV, positive predictive value.
Advanced neoplasia defined as any of the following: 1) adenomas ≥1 cm, 2) high-grade dysplasia, 3) villous histology, or 
4) carcinoma.
Exact CI.
Table 3. Outcomes of Stool Tests for Colorectal Cancer Screening for 
Detection of Advanced Neoplasia Among Alaska Natives by Helicobacter 
pylori Status (n = 304), 2008–2012
Test 
Results

























Immunochemical fecal occult blood test
Positive 7 (33) 10 (7) 3 (43) 11 (8) 10 (36) 21 (8)
Negative 14 (67) 133 (93) 4 (57) 122 (92) 18 (64) 255 (92)
Guaiac-based fecal occult blood test
Positive 6 (29) 44 (31) 2 (29) 23 (17) 8 (29) 67 (24)
Negative 15 (71) 99 (69) 5 (71) 110 (83) 20 (71) 209 (76)
Advanced neoplasia defined as any of the following: 1) adenomas ≥1 cm, 2) high-grade dysplasia, 3) villous histology, or 
4) carcinoma.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. 
Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, 
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